Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEVIATE: Reproxalap in allergic conjunctivitis
NCT03494504Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Mar 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of reproxalap in allergic conjunctivitis (AC), sponsored by Aldeyra Therapeutics. Started Mar 2018; status: completed.
02
Drugs
reproxalap
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT03494504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494504.